Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 2004 Jan;48(1):319–322. doi: 10.1128/AAC.48.1.319-322.2004

FKS1 Mutations Responsible for Selective Resistance of Saccharomyces cerevisiae to the Novel 1,3-β-Glucan Synthase Inhibitor Arborcandin C

Takao Ohyama 1,*, Shunichi Miyakoshi 1, Fujio Isono 1
PMCID: PMC310202  PMID: 14693557

Abstract

Arborcandin C is a novel antibiotic with potent antifungal activity that inhibits 1,3-β-glucan synthase in fungi. We examined spontaneous Saccharomyces cerevisiae mutants which are selectively resistant to arborcandin C and revealed that a single amino acid replacement in Fks1p of Asn470 with Lys or of Leu642 with Ser confers selective resistance on Fks1p mutants.


The 1,3-β-glucan polymer is a major component of the cell wall in yeast and filamentous fungi (11) and is synthesized by 1,3-β-glucan synthase (GS). In Saccharomyces cerevisiae, GS consists of at least two subunits: a putative catalytic subunit encoded by related genes FKS1 and FKS2 (7, 10) and a regulatory subunit, a GTP-bound protein encoded by RHO1 (16). Several types of GS inhibitors, such as echinocandins (5, 13), papulacandins (20), and FR901469 (8), have been identified. GS inhibitors are a new class of antifungal antibiotics with clinical significance because of their strong fungicidal activity and low toxicity (1, 3).

Arborcandins are recently isolated cyclic lipopeptides which inhibit GS from Candida albicans and Aspergillus fumigatus (14) and which also have growth-inhibitory activity (14). Although we reported that arborcandin C noncompetitively inhibited GS (14), the molecular target of the inhibition still remains to be elucidated. In this study, we isolated selective arborcandin C-resistant S. cerevisiae mutants with antibiotic-resistant-GS activity and revealed that two single-amino-acid mutations in Fks1p conferred selective resistance to arborcandin C.

Standard procedures were used for DNA manipulations (17). Genetic manipulations for yeast were carried out as described previously (9). Yeast strains and plasmids used in this study are listed in Table 1. All yeast strains were derivatives of S. cerevisiae YPH250 (18). Yeast cells were grown either in YPDAU medium (2% peptone, 1% yeast extract, 20 μg of adenine sulfate/ml, 20 μg of uracil/ml, 2% glucose) or SD medium (9) supplemented appropriately. FKS1 was cloned by screening the genomic DNA library of the wild-type strain (YPH250) for complementing fks1Δ::LEU2 on SD medium containing 1 μg of FK506/ml. An arborcandin C resistance gene was cloned by screening the genomic DNA libraries of the arborcandin C-resistant mutants ACR79-5 and ACR1A3 for genes that conferred growth in SD medium containing 5 μg of arborcandin C/ml on YPH250. The DNA sequence was determined by automated DNA sequencer model ABI3700 with a dye terminator cycle sequencing kit (Applied Biosystems).

TABLE 1.

Yeast strains and plasmids used in this study

Strain or plasmid Description Reference or source
Plasmids
    pAUR112 Centromere-type shuttle vector Takara Bio, Inc.
    pCE112 Centromere-type shuttle vector derived from pAUR112 This study
    pCE-FKS1 pCE112 containing cloned FKS1 from YHP250 This study
    pCE-FKS1N470K pCE-FKS1 replaced with ACR75-5 mutated region This study
    pCE-FKS1L642S pCE-FKS1 replaced with ACR1A3 mutated region This study
Strains
    YHP250 MATaura3-52 lys2-801 ade2-101 trp11 his3-c200 leu21 18
    ACR75-5 Arborcandin C-resistant mutant derived from YHP250 This study
    ACR1A3 Arborcandin C-resistant mutant derived from YHP250 This study
    fks1Δ MATaura3-52 lys2-801 ade2-101 trp11 his3-c200 leu21 fks1Δ::LEU2 This study
    fks1ΔPGAL10-FKS2 MATaura3-52 lys2-801 ade2-101 trp11 his3-c200 leu21 fks1Δ::LEU2 PGAL10-FKS2::TRP1 This study
    CE-FKS1 fks1ΔPGAL10-FKS2 harboring plasmid pCE-FKS1 This study
    CE-FKS1N470K fks1ΔPGAL10-FKS2 harboring plasmid pCE-FKS1N470K This study
    CE-FKS1L642S fks1ΔPGAL10-FKS2 harboring plasmid pCE-FKS1L642S This study

Growth inhibition was determined by the broth microdilution method in a 96-well microplate using YPDAU medium. Briefly, 104 yeast cells were inoculated into 150 μl of medium in each well and incubated at 30°C for 16 to 24 h in the presence or absence of GS inhibitors. The optical density at 595 nm of the exponentially growing culture was measured by microplate reader (ARVOsx; Perkin-Elmer).

Preparation and measurement of activity of GS from wild-type and mutant S. cerevisiae strains were performed according to the procedure described by Inoue et al. (10) and Cabib and Kang (4), respectively. The solubilized membrane fraction (10) was used as GS.

Isolation of selective arborcandin C-resistant mutants.

Arborcandin C is structurally different from echinocandins and papulacandins (14). To examine whether arborcandin C has a molecular target different from those of known GS inhibitors, we took a genetic approach. Spontaneously resistant S. cerevisiae mutants were isolated at a concentration of 1 μg of arborcandin C/ml on a YPDAU medium plate. We selected two mutants, ACR79-5 and ACR1A3, which are resistant only to arborcandin C, not to any other type of GS inhibitors, for further study. As the echinocandin-type and papulacandin-type inhibitors, we used pneumocandin A0 (2) and F-10748 C1 (15), respectively. As shown in Table 2, both mutants were 100-fold more resistant to arborcandin C than the parental wild-type strain and there was a modest change in the susceptibility to pneumocandin A0 and F-10748 C1. We did not observe significant differences between the wild-type strain and the mutants in their phenotypes, such as their cell morphology and calcofluor white sensitivity phenotypes, which reflect structural changes in the cell wall (data not shown).

TABLE 2.

Susceptibilities of selective arborcandin C-resistant mutants to GS inhibitors

Strain IC50a (μg/ml)
MICb (μg/ml)
Arborcandin C Pneumocandin A0 F-10748 C1 Arborcandin C Pneumocandin A0 F-10748 C1
YHP250 (wild type) 0.083 1.3 0.83 0.5 8 8
ACR79-5 50 0.70 0.75 >64 4 8
ACR1A3 9.2 0.75 3.0 >64 4 16
CE-FKS1 0.086 1.3 0.90 0.5 8 8
CE-FKS1N470K 59 0.88 1.1 >64 4 8
CE-FKS1L642S 14 0.83 4.0 >64 4 16
a

IC50, concentration of compound that gives 50% inhibition of cell growth compared with the control.

b

MIC, minimum concentration of compound that gives 100% inhibition of cell growth compared with the control.

To determine whether the selective resistance of the mutants to arborcandin C was due to a change of sensitivity of GS, the sensitivity of GS from the mutants was tested. As shown in Table 3, GS from either of the resistant mutants was highly resistant to arborcandin C. The 50% inhibitory concentration of arborcandin C against the mutant's GS was more than 100-fold higher than that of arborcandin C against the wild-type enzyme. On the other hand, the sensitivity of both mutant enzymes to the other types of GS inhibitors tested was not significantly changed. These results suggested that the selective resistance of the mutants was due to the selective resistance of GS.

TABLE 3.

Sensitivity of GS from selective arborcandin C-resistant mutants to GS inhibitors

Strain IC50a (μg/ml)
GS sp act (nmol/min/mg of protein)
Arborcandin C Pneumocandin A0 F-10748 C1
YPH250 (wild type) 0.67 0.86 8.7 6.6
ACR79-5 >100 4.8 6.9 3.9
ACR1A3 >100 0.63 1.6 3.3
CE-FKS1 0.26 1.0 5.5 5.9
CE-FKS1N470K >100 5.3 3.5 3.8
CE-FKS1L642S >100 0.80 1.2 3.9
a

IC50, concentration of a compound that gives 50% inhibition of GS activity compared with the control.

Cloning of mutated genes responsible for selective arborcandin C resistance.

To identify the mutated genes in ACR79-5 and ACR1A3, we screened the genomic DNA library of each mutant using the centromere-type vector (pCE112) for plasmids conferring arborcandin C resistance on the wild-type strain. Four and three arborcandin C-resistant colonies were isolated by the transformation with the libraries of ACR79-5 and ACR1A3, respectively. All plasmid DNAs recovered from the resistant transformants conferred arborcandin C resistance (data not shown). Partial sequence analysis of the plasmids revealed that the minimum region conferring arborcandin C resistance from both the mutants contained an FKS1 locus as a complete open reading frame (data not shown). Therefore, it was strongly suggested that the gene mutated in both the resistant mutants was FKS1.

Mutation of Asn470 to Lys or Leu642 to Ser in Fks1p confers selective resistance to arborcandin C.

By DNA sequence analysis of the FKS1 open reading frame, the mutations in ACR79-5 and ACR1A3 were determined to be the replacement of Asn470 with Lys and of Leu642 with Ser in Fks1p, respectively (Fig. 1). We subcloned each of the mutated regions to wild-type FKS1 and examined the effect of each mutation in the fks1Δ PGAL10-FKS2 cells. In the fks1Δ PGAL10-FKS2 strain, FKS2 gene expression was controlled by the GAL10 promoter and suppressed in the presence of glucose. Therefore, the effect of the substitution in Fks1p can be analyzed under the depletion of endogenous Fks1p and Fks2p in the fks1Δ PGAL10-FKS2 cells in glucose medium. The introduction of mutated FKS1 (FKS1N470K or FKS1L642S) to the fks1Δ PGAL10-FKS2 strain conferred selective resistance to arborcandin C, as shown by arborcandin C-resistant mutants ACR79-5 and ACR1A3 (Table 2). Moreover, the GSs from cells with FKS1N470K or FKS1L642S conferred selective resistance to arborcandin C (Table 3). These results show that Asn470 and Leu642 of Fks1p are critical amino acids in the GS-inhibitory activity of arborcandin C and strongly suggest that the target molecule of arborcandin C is Fks1p, the putative catalytic subunit of GS.

FIG. 1.

FIG. 1.

Nucleotide sequence analysis of FKS1 open reading frames of ACR79-5 and ACR1A3. (A) Partial nucleotide sequences of FKS1 from wild-type and arborcandin C-resistant mutants. Arrows, points of nucleotide mutations found in the resistant mutants. (B) Predicted amino acid sequences of Fks1p from the resistant mutants. The substituted residues in the resistant mutants are underlined.

The results we obtained also suggested that Asn470 and Leu642 in Fks1p are topologically proximate. The model of membrane topology of Fks1p was predicted by hydropathy plot analysis (6). In the model, Asn470 and Leu642 exist in the transmembrane domain and cytoplasmic loop domain, respectively, and Asn470 is topologically distant from Leu642 (Fig. 2A). On the other hand, in the model predicted by the PHDhtm server (http://cubic.bioc.columbia.edu/predictprotein), Asn470 and Leu642 exist at the first and third extracellular regions, respectively, and it is possible that these amino acid residues are close to each other (Fig. 2B). Our results support the model of Fks1p by the PHDhtm server and contribute to the understanding of the exact structure of Fks1p.

FIG. 2.

FIG. 2.

Model of the predicted membrane topology of the N-terminal region of Fks1p. Solid line, polypeptide chain; boxes, putative transmembrane helices. (A) Model predicted by hydropathy plot analysis. (B) Model predicted by the PHDhtm server.

Amino acid residues corresponding to Asn470 and Leu642 and the primary structure of the regions around those amino acid residues are well conserved among arborcandin-sensitive fungi (Fig. 3). However, these amino acid residues are also conserved in Cryptococcus neoformans, which is resistant to arborcandins (14). Although C. neoformans has GS and although the unique FKS1 gene of this organism is essential for its growth (19), C. neoformans is resistant to all the known GS inhibitors (8, 12, 20). A common mechanism of resistance to these GS inhibitors, including arborcandins, may exist in C. neoformans.

FIG. 3.

FIG. 3.

Amino acid sequence alignment of Fks proteins from various fungi. The amino acid sequences of S. cerevisiae Fks1p, residues 459 to 483 and 632 to 656, are aligned to the relevant sequences of Fks proteins from C. albicans, A. fumigatus, and C. neoformans (GenBank accession numbers D88815, U79728, and AF102882, respectively). Gray boxes and filled boxes, conserved residues among Fks proteins and mutated residues in arborcandin C-resistant mutants, respectively.

Isolation of the selective arborcandin C-resistant mutants and the identification of amino acids responsible for the resistance provide new insights into the interaction between Fks1p and GS inhibitors. Based on the results of this study, future studies will monitor the direct interaction between arborcandin C and the N-terminal putative extracellular region. Structural analysis of the N-terminal region of Fks1p would also help to improve the antifungal activity of arborcandins.

Nucleotide sequence accession numbers.

Whole nucleotide sequences of FKS1 open reading frames of the wild type, ACR79-5, and ACR1A3 are available in the GenBank database under the accession numbers AY395693, AY395694, and AY395695, respectively.

REFERENCES

  • 1.Abruzzo, G. K., A. M. Flattery, C. J. Gill, L. Kong, J. G. Smith, V. B. Pikounis, J. M. Balkovec, A. F. Bouffard, J. F. Dropinski, H. Rosen, H. Kropp, and K. Bartizal. 1997. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. 41:2333-2338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Adefarati, A. A., O. D. Hensens, E. T. Jones, and J. S. Tkacz. 1992. Pneumocandins from Zalerion arboricola. V. Glutamic acid- and leucine-derived amino acids in pneumocandin A0 (L-671,329) and distinct origins of the substituted proline residues in pneumocandins A0 and B0. J. Antibiot. 45:1953-1957. [DOI] [PubMed] [Google Scholar]
  • 3.Bartizal, K., C. J. Gill, G. K. Abruzzo, A. M. Flattery, L. Kong, P. M. Scott, J. G. Smith, C. E. Leighton, A. Bouffard, J. F. Dropinski, and J. Balkovec. 1997. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2326-2332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Cabib, E., and M. S. Kang. 1987. Fungal 1,3-β-glucan synthase. Methods Enzymol. 138:637-642. [DOI] [PubMed] [Google Scholar]
  • 5.Debono, M., and R. S. Gordee. 1994. Antibiotics that inhibit fungal cell wall development. Annu. Rev. Microbiol. 48:471-497. [DOI] [PubMed] [Google Scholar]
  • 6.Douglas, C. M., F. Foor, J. A. Marrinan, N. Morin, J. B. Nielsen, A. M. Dahl, P. Mazur, W. Baginsky, W. Li, M. el-Sherbeini, J. A. Clemas, S. M. Mandala, B. R. Frommer, and M. B. Kurtz. 1994. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc. Natl. Acad. Sci. USA 91:12907-12911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Eng, W. K., L. Faucette, M. M. McLaughlin, R. Cafferkey, Y. Koltin, R. A. Morris, P. R. Young, R. K. Johnson, and G. P. Livi. 1994. The yeast FKS1 gene encodes a novel membrane protein, mutations in which confer FK506 and cyclosporin A hypersensitivity and calcineurin-dependent growth. Gene. 151:61-71. [DOI] [PubMed] [Google Scholar]
  • 8.Fujie, A., T. Iwamoto, H. Muramatsu, T. Okudaira, I. Sato, T. Furuta, Y. Tsurumi, Y. Hori, M. Hino, S. Hashimoto, and M. Okuhara. 2000. FR901469, a novel antifungal antibiotic from an unidentified fungus no. 11243. II. In vitro and in vivo activities. J. Antibiot. 53:920-927. [DOI] [PubMed] [Google Scholar]
  • 9.Guthrie, C., and G. R. Fink (ed.). 1991. Methods in enzymology, vol. 194. Guide to yeast genetics and molecular biology. Academic Press, Inc., San Diego, Calif. [PubMed]
  • 10.Inoue, S. B., N. Takewaki, T. Takasuka, T. Mio, M. Adachi, Y. Fujii, C. Miyamoto, M. Arisawa, Y. Furuichi, and T. Watanabe. 1995. Characterization and gene cloning of 1,3-β-glucan synthase from Saccharomyces cerevisiae. Eur. J. Biochem. 231:845-854. [DOI] [PubMed] [Google Scholar]
  • 11.Klis, F. M. 1994. Review: cell wall assembly in yeast. Yeast 10:851-869. [DOI] [PubMed] [Google Scholar]
  • 12.Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Kurtz, M. B., and C. M. Douglas. 1997. Lipopeptide inhibitors of fungal glucan synthase. J. Med. Vet. Mycol. 35:79-86. [DOI] [PubMed] [Google Scholar]
  • 14.Ohyama, T., Y. Kurihara, Y. Ono, T. Ishikawa, S. Miyakoshi, K. Hamano, M. Arai, T. Suzuki, H. Igari, Y. Suzuki, and M. Inukai. 2000. Arborcandins A, B, C, D, E and F, novel 1,3-β-glucan synthase inhibitors: production and biological activity. J. Antibiot. 53:1108-1116. [DOI] [PubMed] [Google Scholar]
  • 15.Ohyama, T., Y. Iwadate-Kurihara, T. Hosoya, T. Ishikawa, S. Miyakoshi, K. Hamano, and M. Inukai. 2002. F-10748 A1, A2, B1, B2, C1, C2, D1 and D2, novel papulacandins. J. Antibiot. 55:758-763. [DOI] [PubMed] [Google Scholar]
  • 16.Qadota, H., C. P. Python, S. B. Inoue, M. Arisawa, Y. Anraku, Y. Zheng, T. Watanabe, D. E. Levin, and Y. Ohya. 1996. Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-β-glucan synthase. Science 272:279-281. [DOI] [PubMed] [Google Scholar]
  • 17.Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
  • 18.Sikorski, R. S., and P. Hieter. 1989. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Thompson, J. R., C. M. Douglas, W. Li, C. K. Jue, B. Pramanik, X. Yuan, T. H. Rude, D. L. Toffaletti, J. R. Perfect, and M. Kurtz. 1999. A glucan synthase FKS1 homologue in Cryptococcus neoformans is single copy and encodes an essential function. J. Bacteriol. 181:444-453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.VanMiddlesworth, F., M. N. Omstead, D. Schmatz, K. Bartizal, R. Fromtling, G. Bills, K. Nollstadt, S. Honeycutt, M. Zweerink, G. Garrity, and K. Wilson. 1991. L-687-781, a new member of the papulacandin family of β-1,3-D-glucan synthesis inhibitors. I. Fermentation, isolation and biological activity. J. Antibiot. 44:45-51. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES